Roche Agrees to Nearly $3 Billion Package for ex-US Rights to Sarepta Gene Therapy; China a Major Market

Roche paid $750 million upfront and invested another $400 million in Sarepta Therapeutics of Cambridge, MA to acquire ex-US rights to Sarepta's clinical-stage treatment for Duchenne muscular dystrophy (DMD), a rare disease. Sarepta said there are 60,000 cases of DMD in China alone, though Roche will have to devise a strategy for China insurance reimbursement to succeed in China. As an treatment for a rare condition, the gene therapy will be very expensive. Under the agreement, Sarepta is eligible to receive up to an additional $1.7 billion consisting of regulatory/sales milestones and royalties. More details....

Stock Symbols: (SIX: RO) (NSDQ: SRPT)

Share this with colleagues: